AGAP2 (ArfGAP with GTPase domain, ANK repeat, and PH domain 2) is a member of the ArfGAP protein family, which regulates ADP-ribosylation factor (Arf) GTPases involved in membrane trafficking, cytoskeletal reorganization, and cellular signaling. AGAP2 plays roles in endosomal trafficking, receptor recycling, and modulation of growth factor signaling pathways, such as EGFR and PDGFR. It contains functional domains critical for lipid binding, protein interactions, and GTPase-activating activity, enabling its participation in diverse cellular processes.
Research has linked AGAP2 to cancer progression, particularly in glioblastoma, prostate cancer, and hepatocellular carcinoma, where its overexpression correlates with enhanced cell proliferation, invasion, and metastasis. It may act as an oncogenic driver by promoting PI3K/AKT and MAPK pathway activation. AGAP2 antibodies are essential tools for studying its expression patterns, subcellular localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore its role in disease mechanisms or validate experimental models. Recent studies also suggest AGAP2's involvement in neurological disorders, highlighting its broader biomedical relevance. Developing specific AGAP2 antibodies remains crucial for advancing diagnostic and therapeutic strategies targeting AGAP2-associated pathways.